152 related articles for article (PubMed ID: 1146660)
1. Dopaminergic mechanisms in patients with extrapyramidal disease.
Chase TN; Shoulson I
Adv Neurol; 1975; 9():359-66. PubMed ID: 1146660
[No Abstract] [Full Text] [Related]
2. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
Rinne UK; Sonninen V; Marttila R
Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
[TBL] [Abstract][Full Text] [Related]
3. Brain dopamine turnover and the relief of parkinsonism.
Rinne UK; Sonninen V; Marttila R
Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
[TBL] [Abstract][Full Text] [Related]
4. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
Rondot P; Bathien N; Dumas JL
Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
[No Abstract] [Full Text] [Related]
5. Brain dopamine turnover and the relief of parkinsonism.
Rinne UK; Marttila R; Sonninen V
Arch Neurol; 1977 Oct; 34(10):626-9. PubMed ID: 907536
[TBL] [Abstract][Full Text] [Related]
6. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
Truelle JL; Chanelet J; Bastard J; Six P; Emile J
Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
[TBL] [Abstract][Full Text] [Related]
7. Piribedil--an oral dopamine agonist for treatment of Parkinson's disease.
Sweet RD; Wasterlain C; McDowell FH
Trans Am Neurol Assoc; 1974; 99():258-60. PubMed ID: 4463553
[No Abstract] [Full Text] [Related]
8. Caffeine and the antiparkinsonian response to levodopa or piribedil.
Shoulson I; Chase T
Neurology; 1975 Aug; 25(8):722-4. PubMed ID: 125389
[TBL] [Abstract][Full Text] [Related]
9. Actions of dopaminergic agonists in parkinsonism.
McDowell FH; Sweet R
Adv Neurol; 1975; 9():367-71. PubMed ID: 1096573
[No Abstract] [Full Text] [Related]
10. [Piribedil in the treatment of Parkinson disease (author's transl)].
Nardini M; Sciannandrone R; Fieschi C; De Simone G
Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
[TBL] [Abstract][Full Text] [Related]
11. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
Emile J; Chanelet J; Truelle JL; Bastard J
Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
[No Abstract] [Full Text] [Related]
12. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
Feigenson JS; Sweet RD; McDowell FH
Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
[TBL] [Abstract][Full Text] [Related]
13. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
14. The effect of methiothepin on cerebral monoamine neurons.
Lloyd KG; Bartholini G
Adv Biochem Psychopharmacol; 1974; 10():305-9. PubMed ID: 4846546
[No Abstract] [Full Text] [Related]
15. [New therapeutic indications for a dopamine antagonist, Piribedyl].
Schmitt H; Laubie M; Poignant JC; Krikorian A; Evrard Y; Freyria JL; Arnaud F
Sem Hop; 1978 Mar; 54(5-8):325-34. PubMed ID: 211628
[TBL] [Abstract][Full Text] [Related]
16. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
Callaghan N; Fitzpatrick E; O'Mahony JB
Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
McLellan DL; Chalmers RJ; Johnson RH
Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
[TBL] [Abstract][Full Text] [Related]
18. [Long-term clinical and electrophysiological study of a new dopaminergic agonist in 54 patients with parkinsonism].
Truelle JL; Chanelet J; Bastard J; Six P; Emile J
Sem Hop Ther; 1977 Nov; 53(9):453-6. PubMed ID: 341320
[No Abstract] [Full Text] [Related]
19. Clinical studies of dopaminergic mechanisms.
Chase TN
Adv Biochem Psychopharmacol; 1974; 12(0):427-34. PubMed ID: 4421041
[No Abstract] [Full Text] [Related]
20. [Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
Korf J; van Praagen HM; Lakke JP
Ned Tijdschr Geneeskd; 1975 Sep; 119(36):1373-8. PubMed ID: 241026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
